8-K: Abpro Holdings Confirms Nasdaq Delisting

Abpro Holdings, Inc. has received final notification from the Nasdaq Listing and Hearing Review Council that its securities will be delisted for failure to meet minimum equity requirements.

Summary

• The Nasdaq Listing and Hearing Review Council reaffirmed a decision to delist Abpro Holdings, Inc. securities.
• The delisting follows the company's failure to meet the minimum equity standard requirement under Nasdaq Listing Rule 5550(b)(1) by the February 16, 2026 deadline.
• The company expects Nasdaq to file a Form 25 with the SEC to finalize the delisting and deregistration.
• Common stock and warrants are expected to continue trading on the OTC Pink Market under symbols ABP and ABPWW.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a negative development, as the final loss of a major exchange listing significantly impairs the company's market profile and investor accessibility.

Positives

• Continued availability of trading on the OTC Pink Market provides a venue for liquidity, albeit reduced.

Negatives

• Final confirmation of delisting from the Nasdaq Stock Market.
• Failure to meet minimum equity standards required for continued listing.
• Loss of prestige and institutional investor access associated with a major exchange listing.

Risks

• Limited availability of information and reduced transparency on the OTC Pink Market.
• Increased volatility and reduced liquidity for common stock and warrants.
• No assurance that broker-dealers will continue to make a market in the company's securities.

Future Outlook

The company expects Nasdaq to file a Form 25 with the SEC in the coming days to finalize the delisting and deregistration of its securities.

Management Comments

• The company cautions stockholders and public warrant holders that trading on the OTC Pink Market may be subject to limited availability of information, reduced transparency and liquidity and greater volatility.

Industry Context

StockSavvy.ai notes that this delisting reflects a broader trend of biotech and small-cap firms struggling to maintain capital requirements in a high-interest-rate environment, often leading to a migration from major exchanges to OTC markets.

Comparison to Industry Standards

• The company's inability to maintain Nasdaq listing standards places it in a cohort of distressed small-cap equities that have lost access to primary exchange liquidity.
• Unlike companies that successfully execute reverse splits or capital raises to regain compliance, Abpro has exhausted its appeal process with the Nasdaq Listing and Hearing Review Council.

Stakeholder Impact

• Shareholders face increased volatility and reduced liquidity.
• Institutional investors may be forced to divest due to internal mandates regarding exchange-listed securities.

Next Steps

• Nasdaq to file Form 25 with the SEC.
• Deregistration of securities under Section 12(b) of the Exchange Act.
• Continued monitoring of OTC Pink Market trading activity.

Key Dates

Recommendation

The final delisting from a major exchange is a significant negative catalyst that typically leads to institutional selling and reduced valuation multiples due to the loss of liquidity and transparency.

Keywords

delisting, Nasdaq, OTC Pink, equity compliance, Abpro Holdings, ABP, ABPWW